Whole brain radiotherapy plus simultaneous in-field boost with image guided intensity-modulated radiotherapy for brain metastases of non-small cell lung cancer

Table 2 Univariate and multivariate analysis of IC-PFS, median survival and incidence of grade 2 leukoencephalopathy

	IC-PFS (m) Median	Univariate p-value	Multivariate p-value	MS(m)	Univariate p-value	Multivariate p-value	Leukoencephalopathy No. of patients (%)	Univariate p-value	Multivariate p-value
Gender
Male	6	0.020	0.869	7	0.019	0.983	3/20 (15.5)	0.024	0.562
Female	18			18			5/9 (55.6%)
Age (years)
≥60	8	0.628		8	0.719		5/18 (27.8)	0.794
<60	12			12			3/11 (27.3)
KPS scores
≥70	12	0.251		12	0.223		5/19 (26.3)	0.833
<70	3			4.4			3/10(30)
Pathology
Adenocarcinoma	14	0.015	0.519	14	0.011	0.553	6/13 (46.2)	0.044	0.084
Non-adenocarcinoma	3			4.4			2/16 (12.5)
RPA class
2	12	0.266		12	0.185		5/19 (26.3)	0.833
3	3			4.4			3/10 (30.0%)
GPA scores
0-1	6	0.331		7	0.188		4/13 (30.8)	0.730
1.5-3.5	14			14			4/16 (25%)
SIR scores
≤5	3	0.001	0.044	4.4	<0.001	0.021	5/13 (38.5)	0.238
>5	14			14			3/16 (18.75)
History of EGFR-TKI treatment
Yes	16	0.026	0.035	18	0.022	0.040	7/11 (63.6)	0.001	0.010
No	6			7			1/18 (5.6)
Number of lesions
<3	14	0.005	0.036	14	0.007	0.048	6/15 (40.0)	0.122
≥3	3			6			2/14 (14.3)
Maximum lesion volume
<3 cc	14	0.209		14	0.081		4/12 (33.3)	0.561
≥3 cc	4.4			6			4/17 (23.5)
Total volume of lesions
<7 cc	14	0.032	0.232	14	0.037	0.256	5/15 (33.3)	0.474
≥7 cc	3			6			3/14 (21.4)
Total	10			10			8/29 (27.6)

Abbreviations: IC-PFS = intracranial progression-free survival; MS = median survival; m = month; RPA = recursive partitioning analysis; GPA = graded prognostic assessment; SIR = score index for radiosurgery in brain metastases; EGFR-TKI = epidermal growth factor receptor- tyrosine kinase inhibitor.

ISSN: 1748-717X